This study investigated the impact of testosterone on myocardial ischemia-reperfusion injury and corresponding intracellular calcium ([Ca 2؉ ] i ) metabolism. Nonorchiectomized mature male Wistar rats were randomly assigned to placebo, a single dose of testosterone undecanoate, or 5␣-dihydrotestosterone. In a further series, orchiectomized rats were treated with placebo. After 2 wk of treatment, the hearts were removed and placed in a Langendorff setup. T HE INCIDENCE OF coronary heart disease in premenopausal women is much lower than in age-matched men. This significant gender difference has been related to a protective role of 17␤-estradiol (1). Studies in experimental animals have demonstrated multiple beneficial effects of estrogens on the cardiovascular system, including amelioration of ischemia-and reperfusion-induced myocardial injury (2). However, randomized placebo-controlled clinical trials have failed to find evidence for a protective role of exogenously administered estrogens, possibly because of procoagulatory and proinflammatory activity of estrogens (3, 4). In contrast, the role of androgens for cardiovascular health has been largely neglected.
T HE INCIDENCE OF coronary heart disease in premenopausal women is much lower than in age-matched men. This significant gender difference has been related to a protective role of 17␤-estradiol (1) . Studies in experimental animals have demonstrated multiple beneficial effects of estrogens on the cardiovascular system, including amelioration of ischemia-and reperfusion-induced myocardial injury (2) . However, randomized placebo-controlled clinical trials have failed to find evidence for a protective role of exogenously administered estrogens, possibly because of procoagulatory and proinflammatory activity of estrogens (3, 4) . In contrast, the role of androgens for cardiovascular health has been largely neglected.
Anabolic androgenic steroids have been associated with myocardial ischemia, sudden cardiac death, and hypertension in athletes (5) , leading to the view that androgens are detrimental for the cardiovascular system. However, anabolic androgenic steroids consist of a variety of different steroids with differing pharmacological properties. Moreover, the incidence of cardiovascular morbidity associated with anabolic androgenic steroid use has been difficult to determine, because of the clandestine nature of steroid use in athletes. No clinical study has yet demonstrated a conclusive link between anabolic androgenic steroids and fatal cardiovascular events. Epidemiological data (6) and an intervention study (7) rather suggest either a neutral or a beneficial effect of natural circulating androgens on coronary heart disease in males. Testosterone in men declines with age, and supplementation of elderly men with testosterone has recently received considerable attention (8) . Furthermore, the use of testosterone esters like testosterone enanthate in males induces transient supraphysiological androgen levels after im application. Thus, evaluation of the role of testosterone for cardiovascular health is of growing importance. The association of anabolic androgenic steroids with myocardial infarction and sudden cardiac death (5) suggests that androgens may negatively affect myocardial tolerance to ischemia. We, therefore, tested the effects of testosterone treatment on the ventricular dysfunction caused by global ischemia, followed by reperfusion in an isolated rat heart preparation. In addition, because intracellular free calcium overload is of major importance for ischemia-reperfusion injury (9), we used aequorin bioluminescence to assess intracellular calcium ([Ca 2ϩ ] i ) handling during myocardial ischemia-reperfusion.
Materials and Methods

Animal model
A total of 104 mature male Wistar rats at an age of 8 -10 wk and a body weight (bw) of 180 -200 g were obtained from Charles River Breeding Laboratories (Kisslegg, Germany). Animals received water and normal rat chow ad libitum. In two consecutive series, rats were randomly Abbreviations: bw, Body weight; [Ca 2ϩ ] i , intracellular calcium; CPP, coronary perfusion pressure; DHT, 5␣-dihydrotestosterone; LV, left ventricular; LVDP, LV developed pressure (systolic pressure Ϫ diastolic pressure); LVEDP, LV end-diastolic pressure; LVw, LV weight; n.s., not significant; ORX, orchiectomized or orchiectomy; P, placebo; P s , time from peak P s to 90% of relaxation; PVDF, polyvinylidene difluoride; SERCA, sarcoplasmic Ca 2ϩ -ATPase; TUD, testosterone undecanoate; Vol max , volume of maximal developed pressure. assigned to one of three experimental groups: I, nonorchiectomized and placebo (P) (n ϭ 27); II, nonorchiectomized and a single dose of the long-lasting testosterone preparation [testosterone undecanoate (TUD), 500 mg/kg bw] im (n ϭ 32); and III, orchiectomized and placebo (ORXϩP) (n ϭ 30). Treatment was begun 14 d before removal of the hearts. Because we wanted to find out whether favorable effects of the aromatizable testosterone ester (TUD) could be related to estrogen generation from TUD, we included in the second series a group receiving 5␣-dihydrotestosterone (DHT), a nonaromatizible androgen. Nonorchiectomized rats received a sc implantation of DHT (75 mg/pellet per 21-d release) (n ϭ 15).
TUD was provided by Jenapharm GmbH & Co. KG (Jena, Germany). DHT time-release pellets were manufactured by Innovative Research of America (Sarasota, FL). TUD is available in ampoules containing 1000 mg of the ester in 4 ml of castor oil. As placebo we administered the pure castor oil without TUD and time-release pellets without any DHT, respectively. Dosages of TUD (10) and DHT (11) were chosen to achieve supraphysiological testosterone and DHT concentrations.
The studies were conducted according to the guidelines of the American Physiological Society Principles for Research Involving Animals and Human Beings.
Isolated heart
Isolated hearts were dissected and perfused retrogradely as described previously (12) . The hearts were paced at 5 Hz, coronary flow was set to 12 ml/min⅐g heart weight except during no-flow ischemia, and temperature was controlled at 37.0 Ϯ 0.3 C. Isovolumic left ventricular (LV) developed pressure (LVDP) and LV end-diastolic pressure (LVEDP) were measured at an intracardiac balloon volume of 50% of volume of maximal developed pressure (Vol max ) after a pressure volume curve was obtained (13 
LV pressure recording
LV pressure tracings were digitized with a 12-bit analog-digital converter (sampling rate, 1 kHz) and stored on magnetic disk. The digital signal of the LV pressure tracing was further analyzed using custom software to obtain the following parameters: LVDP, LV systolic pressure, LVEDP, and T90 (i.e. time from peak P s to 90% of relaxation).
Analysis of calcium overload in the first minute of reperfusion
Analysis of [Ca 2ϩ ] i was performed as previously described (12) . To analyze Ca 2ϩ overload occurring in the first minute of reperfusion, the following parameters were used: [Ca 2ϩ ] endisch was end-ischemic [Ca 2ϩ ] i ; peak was the initial peak of Ca 2ϩ signal in the first minute of reperfusion, reflecting the first Ca 2ϩ influx; Oscill max was the maximum of the first 10 transients of Ca 2ϩ oscillations in the first minute of reperfusion, reflecting the amount of Ca 2ϩ released from the overloaded sarcoplasmatic reticulum during each oscillation; I (0 -60) was the time integral of the first 60 sec of reperfusion, respectively, normalized by L max (t), a global Ca 2ϩ overload index. The time integral for I (0 -60) was chosen according to preliminary experiments, demonstrating that the major part of the peak of the reperfusion-induced Ca 2ϩ overload is over within 1 min and that no significant differences could be detected for light integral measurements of at least 1 min (12). End-ischemic calcium was calculated directly before onset of reperfusion.
Experimental protocol (aequorin experiments)
After the aequorin loading procedure, the temperature was increased to 37 C within 10 min, and the hearts were paced at 5 Hz. After steadystate conditions were reached, a pressure-volume relationship was obtained to determine the volume at peak developed pressure (Vol max ) as previously described (13) . To achieve comparable loading conditions (i.e. balloon volumes) in hearts of different sizes, function was compared at 50% of Vol max , the volume at maximum developed. LV volume was set to 50% of Vol max and kept constant for the remainder of the experiment. (12) .
Aequorin light signals were recorded using the four-channel recorder in parallel with the LV pressure and coronary perfusion pressure tracings and were digitized, stored, and analyzed as described above for the LV pressure tracings. Briefly, at the end of each experiment, the heart was perfused with a solution containing 20 mmol/liter Ca 2ϩ and Triton X-100 to lyse the aequorin-loaded cells and expose all of the remaining aequorin to Ca 2ϩ . This resulted in an instantaneous burst of light, subsequently declining to baseline within 10 -20 min. The area under the curve was integrated to obtain a value for the total amount of light (L max ) emitted from the aequorin loaded into the myocytes. The ratio of the light signal vs. L max is the fractional luminescence, which was converted into [Ca 2ϩ ] i concentrations by the use of a calibration curve derived in vitro (14) .
The wave-averaged signals were analyzed for peak systolic Ca 2ϩ and diastolic Ca 2ϩ parallel to the analysis of the mechanical parameters.
Calculation of s , d , and relative wall thickness
The s , d (i.e. peak systolic and end-diastolic circumferential wall stress, respectively), and relative wall thickness, assuming spherical isovolumic conditions, were calculated as previously described (13 Tissue preparation. Myocardial tissue, which was not treated with Triton X-100, was snap-frozen in liquid nitrogen immediately after explantation of the heart. Then, 1.22 Ϯ 0.14 g myocardium from the free LV wall was powdered in liquid nitrogen and thawed on ice in three volumes of chilled preparation buffer [sucrose 300 mm, phenylmethy-sulfonylfluoride 1 mm, piperazine-N,N-bis(2-ethanesulfonic acid) 20 mm, EDTA 10 mm, NaH 2 PO 4 50 mm (pH 7.4)] as described by Mü nch et al. (15) . Care was taken to dissect myocardial tissue from connective tissue, vessels, and epicardium. Samples were minced 3 ϫ 30 sec at 4 C with an Ultra Turrax T8 (Janke & Kunkel KG, IKA-Werke, Staufen i. Breisgau, Germany) followed by homogenization with a glass-Teflon potter (B. Braun AG, Melsungen, Germany). After washing procedures, we exposed membranes to the secondary antibody, a peroxidase-conjugated antibody (1:2500). Proteins were detected by an enhanced chemoluminescence assay (ECL Kit, AmershamLife Science, Buckinghamshire, UK), exposed to x-ray film (Kodak X-OMAT Engineering, Eastman Kodak Co., Rochester, NY), and evaluated densitometrically with a commercially available computer program (ImageQuant, Molecular Dynamics, Krefeld, Germany). Protein levels were normalized to overall cardiac protein recovered from the myocardium, as determined by Bradford's assay, and expressed as densitometric units per microgram of protein. Three independent Western blots were performed for each antibody. The staining of the protein bands of the Ca 2ϩ -regulatory proteins on PVDF membranes (Western blots) with Ponceau S solution showed high transfer efficiency. The position of the corresponding protein bands was verified with two markers giving molecular weight.
Materials. Salts were high grade and were purchased from Merck (Darmstadt, Germany); piperazine-N,N-bis(2-ethanesulfonic acid) and phenylmethy-sulfonylfluoride were from Sigma. The 30% acrylamide/ bisacrylamide was from Bio-Rad (Hercules, CA). The primary antibody used for SERCA 2a detection was a mouse monoclonal IgG 1 antibody against canine SERCA 2a protein (Affinity BioReagents Inc., Golden, CO). The antiphospholamban antibody was a mouse monoclonal IgG antibody against canine phospholamban purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). The antibody against calsequestrin was a polyclonal rabbit antibody against canine calsequestrin from Swant (Bellinzona, Switzerland). The antibody against ryanodine-receptor was a rabbit polyclonal antibody (Affinity BioReagents Inc.), and the antibody against the Na ϩ /Ca 2ϩ -exchanger was a polyclonal rabbit anti-NCX antibody from Swant. Secondary antibodies were either monoclonal sheep antimouse IgG peroxidase conjugated or goat antirabbit IgG conjugated with peroxidase from Sigma Immunochemicals (St. Louis, MO).
Immunoassays
The blood samples were allowed to clot, and the sera were separated by centrifugation and stored at Ϫ20 C until assayed.
Serum testosterone was determined by a commercially available RIA (Diagnostic Products Corp., Los Angeles, CA) with a sensitivity of 0.06 ng/ml. The intra-and interassay variance ranged from 6 -15% and 9 -16%, respectively. Serum DHT was also determined by a commercially available RIA (Diagnostic Systems Laboratories, Sinsheim, Germany) with a sensitivity of 0.004 ng/ml. The intra-and interassay variance ranged from 3-6% and 5-12%, respectively.
Statistical analysis
Data are reported as mean Ϯ sem. With four experimental groups, six statistical comparisons are conceivable. Testing for this high number of comparisons with multifactorial ANOVA would overcorrect significance levels. Therefore, we limited the statistical analysis to biologically meaningful comparisons. Comparison of variables between two groups was made by using the unpaired Student's t test. Bonferroni's correction for multiple comparisons was applied to yield a significance level of 0.05:5 ϭ 0.01. Calculations were performed by a commercially available program, StatView SE ϩ Graphics (Brainpower Inc., Calabasas, CA).
Results
Animal characteristics and hormone determination
The bw, LVw (LV weight)/bw ratio, and serum testosterone concentrations were determined 2 wk after single-dose treatment (Table 1 ). The bw was not significantly different between the treatment groups. LVw/bw ratio was significantly higher after TUD administration vs. ORXϩP (P Ͻ 0.008). Serum DHT and testosterone levels were significantly lower in the ORXϩP-treated animals and significantly higher in the DHT-/TUD-treated animals, respectively. Endogenous testosterone was suppressed in DHT-treated animals due to suppression of pituitary gonadotrophs.
Treatment effects on baseline cardiac performance
Before ischemia, no significant differences in mechanical function were observed between TUD, DHT, ORXϩP, and P.
Cardiac function during ischemia and reperfusion
After the beginning of no-flow ischemia, LVDP declined to zero within 5 min in all groups (Fig. 1) . Ischemic contracture developed after approximately 5 min up to nearly 38 mm Hg. At the end of the ischemic period, resting pressure declined slightly to nearly 29 mm Hg in all groups. No significant differences in mechanical function or resting pressure, respectively, could be seen up to the end of ischemia between the treatment groups. On reperfusion, the contractile function was significantly improved in testosterone (i.e. TUD and DHT)-treated rats (vs. ORXϩP); at the end of the reperfusion period, LVDP was higher (Fig. 1) , whereas LVEDP was significantly reduced (Fig. 2) . The improved mechanical function under testosterone treatment resulted in a significantly lower coronary perfusion pressure (CPP) vs. ORXϩP/P (Fig. 3) . malized to preischemic values) was significantly elevated in ORXϩP rat hearts vs. TUD-treated rat (Fig. 4) . Peak ischemic calcium, as represented by the initial peak of the [Ca 2ϩ ] i signal in the first minute of reperfusion was nonsignificantly elevated in ORX hearts, the peak systolic amplitude of the first 10 transients of Ca 2ϩ oscillations was significantly increased in ORXϩP vs. P (ORXϩP, 2.63 Ϯ 0.08, vs. P, 1.99 Ϯ 0.24; P Ͻ 0.01) as well as diastolic level of the first 10 transients of Ca 2ϩ oscillations compared with TUD hearts (ORXϩP, 1.04 Ϯ 0.12; TUD, 0.41 Ϯ 0.09; P Ͻ 0.01). Calcium integral of the first 60 sec of reperfusion normalized by L max was significantly increased in ORXϩP-treated vs. TUDtreated rats (Fig. 5) . ] i was significantly elevated in orchiectomized rat hearts compared with TUD-treated rats. *, P Ͻ 0.01. (P, n ϭ 27; TUD, n ϭ 32; DHT, n ϭ 15; ORXϩP, n ϭ 30).
Expression of calcium regulatory proteins [phospholamban/ Na
Discussion
In our in vitro model, we demonstrated for the first time a reduced susceptibility to myocardial ischemia-reperfusion injury after the administration of long-lasting supraphysiological androgen preparations (i.e. TUD and DHT). The functional recovery was significantly improved, demonstrated by a significantly higher LVDP and lower LVEDP (vs. P and ORXϩP). This effect can partly be explained by a lower end-ischemic [Ca 2ϩ ] i leading to decreased [Ca 2ϩ ] i overload in the postischemic period as well as a reduced systolic [Ca 2ϩ ] i oscillation. Accordingly, orchiectomy was associated with an impaired recovery from ischemia.
Two weeks after TUD administration, a significant cardiac hypertrophy (vs. ORXϩP) could be observed, characterized by an increase of LVw/bw ratio. This TUD-induced hypertrophy had no negative effects on cardiac performance in the preischemic period.
Measurements of [Ca 2ϩ ] i during cardiac ischemia and reperfusion are of interest because of the potential role that changes in [Ca 2ϩ ] i may play in contractile failure and in the initiation of ischemic arrhythmias and cell damage (9) . In our study, the recovery of contractile function was significantly improved in all androgen-treated rats (TUD and DHT vs. ORXϩP); at the end of the reperfusion period LVDP was higher, whereas CPP and LVEDP were significantly reduced. Analysis of end-ischemic [Ca 2ϩ ] i signaling revealed significantly lower levels in the TUD group. In the ORXϩP group, significantly higher systolic [Ca 2ϩ ] i oscillations were found, which might enhance further cell damage.
This protection from reperfusion injury by testosterone could not be explained by an influence on the expression of classical calcium-regulatory proteins. We could not observe quantitative differences in the protein levels of phospholamban, Na ϩ /Ca 2ϩ -exchanger, ryanodine-receptor type 2, or SERCA 2a between groups. However, we cannot exclude differences in activity of these proteins [e.g. due to changes in phosphorylation status (18)]. Testosterone might also prolong intracellular acidification and might protect the myofilaments against reperfusion injury (19) .
[Ca 2ϩ ] i overload during early reperfusion is one cofactor that is responsible for reperfusion injury. The ability of the myocardial cell to eliminate [Ca 2ϩ ] i overload to restore normal calcium homeostasis is related to the amount of [Ca 2ϩ ] i overload at the beginning of reperfusion (20) . In our study [Ca 2ϩ ] i overload indices were elevated in ORX-treated vs. TUD-treated rat hearts. The increased [Ca 2ϩ ] endisch in the ORXϩP group might have further impact on the calcium sensitivity of the myofilaments. Decreased responsiveness of the myofilaments without desensitization to calcium has been shown to occur during the reperfusion period; it impairs contractile performance, and was associated with a transient calcium overload after initiation of reperfusion (21) . Calcium overload during reperfusion is able to activate a calcium-sensitive neutral protease (calpain), which may partially cleave the ryanodine receptor and reduce its ability to release sarcoplasmic reticulum calcium (22) . This dosedependent effect might lead to myofilamentary degradation and consecutive reduced calcium sensitivity. Restoration of myofibrillar integrity after reperfusion of the myocardium will last for more than the postobservation period of 60 min of our study. Summarizing, the level of increased endischemic calcium is able to initiate various effects that are associated with impaired functional recovery of the postischemic myocardium.
Previous studies revealed that administration of testosterone improves coronary vasomotion by NO-dependent (23) and independent ways (24) . Intracoronary administration of testosterone was able to cause coronary dilatation in men with established coronary artery disease (25) . Coronary relaxation was found to be present in estrogen as well as in testosterone-treated coronary arteries, with 17␤-estradiol being more potent than testosterone. Both sex hormones are acting by inhibiting the prostaglandin F 2ϰ -and depolarization-induced, calcium-mediated coronary contraction (26) . The improved postischemic recovery in our study might be supported by an improved coronary vasomotion allowing increased coronary blood flow during reperfusion and, therefore, reduced myocardial reperfusion injury. In our study, the recovery from global ischemia was improved by both TUD and DHT, suggesting that it is related to the androgenic activity of both preparations. However, it seemed that TUD treatment was more effective than the DHT. This might be related to the additional aromatization of TUD to estrogens, which does not occur with DHT treatment. Nevertheless, the improved coronary perfusion pressure might also be a result of decreased postischemic diastolic pressure and thus decreased compression of the myocardium on the microvasculature.
However, because no direct measurements of coronary blood flow were performed in our study, only indirect evidence is given by a significantly increased CPP in the reperfusion period in P as well as in ORXϩP rats, compared with TUD-or DHT-treated rats (Fig. 3 ). This suggests a decreased microcirculatory resistance by an androgen-induced dilatation of macro-and microvessels. The improved CPP may be a result of decreased postischemic diastolic pressure, and thus a decreased compression of the myocardium on the microvasculature is possible.
Furthermore, in a recent study we have shown that testosterone administration leads to an induction of cardiac IGF-I mRNA expression and its downstream target phosphorylated AKT Ser(473) (27) . Interestingly, IGF-I is an important regulator of vascular function by stimulating NO release from cultured vascular endothelium (28) . In addition, both IGF-I administration and phosphorylated AKT Ser(473) activation have been shown to protect against ischemic reperfusion damage in experimental animals by inhibiting apoptosis (29, 30 ). Thus, it seems possible that up-regulation of antiapoptotic pathways by androgens contributes to the protective effects of androgens observed in this study.
There are some limitations of our study. Because the hearts were either stored in liquid nitrogen at Ϫ70 C immediately after the end of the experiment for analysis of the calcium regulatory proteins or lysed with Triton X-100 for calibration of the [Ca 2ϩ ] i signal, no myocardium was harvested to perform histological analysis. Possible reperfusion-induced morphological alterations due to calcium-induced disruption of the myocytes could therefore not be analyzed.
In conclusion, testosterone administration significantly improved the functional recovery of the myocardium after global no-flow ischemia, which was correlated with a lower [Ca 2ϩ ] i overload phenomenon during reperfusion. This protective effect seems to be primarily androgen mediated.
